Skip to main content

Table 2 2004 Cairo and Bishop criteria for Tumor Lysis Syndrome

From: Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report

Variable

Grade 0

Grade I

Grade II

Grade III

Grade IV

Grade V

Creatinine

None

1.5 X ULN

˃1.5–3.0 X ULN

˃3.0–6.0 X ULN

˃6.0 X ULN

Death

Cardiac arrhythmia

None

Intervention not indicated

Nonurgent medical intervention indicated

Symptomatic and incompletely controlled medically or controlled with device (e.g., defibrillator)

Life-threatening (e.g., arrhythmia associated with CHF, hypotension, syncope, shock)

Death

Seizures

None

 

One brief, generalized seizure; seizure(s) well controlled by anticonvulsants, or infrequent focal motor seizures not interfering with ADL

Seizures in which consciousness is altered; poorly controlled seizure disorder; with breakthrough generalized seizures despite medical intervention

Seizures of any kind which are prolonged, repetitive, or difficult to control (e.g., status epilepticus, intractable epilepsy)

Death

  1. ADL activities of daily living, CHF congestive heart failure, ULN upper level of normal